2025 VA/DoD Lipid Guidelines: Key Updates for Practice

Clinicians frequently seek evidence-based strategies to optimize cardiovascular health. Recently, updated lipid management guidelines from the U.S. VA and DoD outlined essential changes for patient care. Therefore, these recommendations help clinicians refine cardiovascular disease risk reduction in diverse clinical settings.

Overview of the Updated Lipid Management Guidelines

The guideline panel systematically evaluated clinical trials published through January 2025. Furthermore, the team formulated 24 evidence-based recommendations using the GRADE methodology. Notably, the panel eliminated the previous advice against routine lipid monitoring. Clinicians should now monitor lipid panels to confirm therapeutic response and treatment adherence. Consequently, this adjustment aligns clinical practice with standard laboratory follow-up needs worldwide.

Primary Prevention: Risk Calculators and Biomarkers

For primary cardiovascular prevention, the panel officially recommends the PREVENT risk calculator. In addition, this tool replaces older equations to improve 10-year event prediction accuracy. Moderate-intensity statins remain the primary recommendation for individuals facing elevated cardiovascular risk. Similarly, physicians should consider statin therapy for patients presenting with intermediate calculated risk. However, clinical uncertainty often complicates treatment decisions in intermediate-to-high risk categories. Therefore, the guidelines endorse coronary artery calcium testing to clarify individual risk. Additionally, the authors recommend a one-time lipoprotein(a) measurement to identify enhanced risk. This laboratory assessment proves especially useful for individuals with unexplained premature atherosclerosis risk.

Secondary Prevention and Advanced Combination Therapies

In secondary prevention, the guideline embraces intensive lipid-lowering protocols. Specifically, very high-risk patients with established cardiovascular disease require potent LDL-C reduction. Clinicians should initiate high-intensity or maximally tolerated statin therapy for these patients immediately. Moreover, the panel recommends adding ezetimibe or PCSK9 inhibitors to achieve targets. Hence, combination therapy offers superior risk reduction compared to statin monotherapy alone.

Special Populations and Statin Intolerance Options

The updated guidance also introduces key recommendations for specific high-risk groups. For instance, adults living with HIV should receive moderate-intensity statins regardless of calculated 10-year risk. This recommendation directly addresses chronic immune activation and heightened vascular vulnerability in HIV. Furthermore, clinicians encounter real-world challenges when patients report significant statin intolerance. Fortunately, several viable alternatives now exist to manage dyslipidemia effectively. Consequently, doctors can prescribe bempedoic acid, ezetimibe, fibrates, or PCSK9 monoclonal antibodies. Thus, clinicians can provide personalized lipid lowering even in complex intolerance scenarios.

Frequently Asked Questions

Q1: What risk estimation tool do the new lipid guidelines recommend for primary prevention?

The updated guideline recommends the PREVENT calculator to estimate 10-year cardiovascular risk accurately. Therefore, clinicians can identify at-risk patients earlier and tailor preventive medical therapies appropriately.

Q2: Why should clinicians test lipoprotein(a) levels according to the update?

The guideline advises one-time lipoprotein(a) testing to identify patients with enhanced cardiovascular risk. In fact, elevated lipoprotein(a) refines risk stratification and helps guide earlier clinical intervention.

Q3: How should clinicians manage very high-risk secondary prevention patients?

Clinicians should prescribe maximally tolerated statin therapy combined with ezetimibe or PCSK9 inhibitors. Consequently, this combination strategy provides potent LDL-C reduction to prevent recurrent vascular events.

References

1. Arnold MJ et al. A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction. Ann Intern Med. 2026 Sep 15. doi: 10.7326/ANNALS-26-01374. PMID: 42735406.
2. Al Rifai M, Blumenthal RS, Stone NJ, et al. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021;68:2-6.
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.